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Introduction: Arhinia, congenital absence of the nose, is a rare malformation. We present the third reported case
of arhinia accompanied by hypogonadism and demonstrate that this is due to gonadotropin deficiency.
Case presentation: A 13-year-old Caucasian boy with congenital arhinia presented for evaluation of delayed
puberty and micropenis. We examined genes known to be associated with hypogonadotropic hypogonadism for
mutations and performed a chromosomal microarray to assess copy number variation.
Conclusion: No mutations in KAL1, FGFR1, PROK2, PROKR2, FGF8, CHD7 and GnRHR were identified in our patient
and there were no copy number variations observed that would explain the phenotype. Though studies are limited
in such patients, we suggest that hypogonadotropic hypogonadism is associated with arhinia and that the two
entities likely result from a common genetic cause that affects early nasal development and gonadotropin-releasing
hormone neuron formation or migration.Introduction
Arhinia, congenital absence of the nose, is a rare con-
genital malformation. Only 36 cases have been reported
in the literature to date, but most reports have focused
on the surgical reconstruction of the nose with little
attention to other hormonal defects associated with
the malformation [1]. Although a few cases have been
attributed to chromosomal abnormalities, most are
idiopathic [2-6]. Features associated with arhinia in-
clude microphthalmia, choanal atresia and cleft palate
[1-5]. A single report describes hypogonadism in two
male patients with arhinia [7], with only a single gen-
etic locus evaluated as a mechanistic link between the
two conditions. Mutations in genes known to be in-
volved in nasal development have also been sought, but
none of the reported cases of arhinia have been asso-
ciated with such mutations [1,3,7].
The association of anosmia (absence of the sense of
smell) and hypogonadotropic hypogonadism is known as
Kallmann syndrome and is far more common than
arhinia [8-12]. Hypoplasia of the olfactory bulbs is a fre-
quent finding and other midline defects occur as well.* Correspondence: Jeanie-tryggestad@oushc.edu
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distribution, and reproduction in any mediumMutations in KAL1, FGFR1 and other genes have been
shown to lead to these conditions, but the majority of
cases have no identifiable cause [8-12].
The development of the nose and the origin and mi-
gration of the cells destined to become the hypothal-
amic neurons controlling gonadotropin secretion are
embryonic-related events. Thus, in the case presented,
we sought a genetic cause by examining in detail the
structure of genes known to be associated with hypo-
gonadotropic hypogonadism and/or Kallmann syn-
drome as well as by a genome-wide assessment of copy
number variation.Case presentation
A 13-year-old Caucasian boy with congenital arhinia
presented for evaluation of delayed puberty and micro-
penis. He was born at 32 weeks gestation weighing
2045g. The absence of his nose resulted in significant
respiratory distress at birth necessitating resuscitation
and subsequent tracheostomy, which was maintained
until age 2 years. He also had a cleft lip and palate that
were repaired in infancy. He had no other dysmorphic
features, notably no microphthalmia. He met develop-
mental milestones appropriately. No family history of
arhinia, anosmia, delayed puberty or hypogonadism
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the most striking feature on physical examination. His
height was 161.6cm (50th percentile for age and sex). His
weight was 79.9kg (greater than the 97th percentile for
age and sex). He appeared of normal intelligence and was
taking advanced placement classes in school. On genital
examination, his left testicle could not be palpated. His
right testis was 2mL in volume and descended into his
scrotum. The stretched penile length was 3.7cm (two
standard deviations below the mean for his age). His pubic
hair was Tanner stage 2. Subsequent to this examination,
orchiopexy of his left testicle had been attempted, but on
exploration the testis was noted to be small and of poor
quality, resulting in orchiectomy.
Our patient’s bone age was 14 years by the standards
of Greulich and Pyle [13] at chronological age 13 years
and 10 months, which is slightly advanced for hypo-
gonadotropic hypogonadism, but could be explained
by his obesity. Computed tomography imaging with
three-dimensional reconstructions of his facial bones
revealed a lack of nasal bones, the absence of sinus
cavities and lacrimal glands, and maxillary hypoplasia.
A Smell Identification Test was administered; this
consists of four booklets containing 10 scratch and
sniff odorants. The test is derived from basic psycho-
logical test measurement theory and focuses on the
comparative abilities of individuals to identify a num-
ber of odorants at the supra-threshold level [14]. The
individual’s score of correctly identified odorants is
compared to scores of normal individuals of the same
age and gender using tables provided in the adminis-
tration manual. Only 11 of 40 possible smells were
identified, diagnostic of anosmia as the test is designed
such that someone unable to smell would guess the
correct answers 25% of the time.
Serum was obtained for measurements of gonado-
tropin levels and testosterone and whole blood for
gene testing. His karyotype was 46,XY with no struc-
tural or numerical anomalies. Gonadotropin and tes-
tosterone measures at 13 years of age were consistent
with severe hypogonadotropic hypogonadism. His level
of luteinizing hormone was <0.1IU/L (expected range
for age, 0.2 to 5.0IU/L) and follicle-stimulating hor-
mone was 0.3IU/L (expected range for age, 1.2 to
5.8IU/L). At 13 years of age, his testosterone measured
1.1nmol/L (expected range for pre-pubertal males <0.7
to 0.8nmol/L). A pathological examination of the
extirpated gonad revealed tissue consistent with atro-
phic testis.
His DNA was screened for rare sequence variants in
the genes KAL1, FGFR1, PROK2, PROKR2, FGF8 and
GnRHR by Dr William Crowley at the University of
Massachusetts. These genes were selected for examin-
ation because of their known association with Kallmannsyndrome and/or hypogonadotropic hypogonadism. Rare
sequence variants were defined as DNA sequence varia-
tions with minor allele frequency of less than 1% in
normal healthy controls. Screening for rare sequence
variants in the KAL1, FGFR1, PROK2, PROKR2, FGF8
and GnRHR genes were all negative. Sequencing for the
coding region of CHD7 was provided by Dr. Shibo Li at
the University of Oklahoma Health Sciences Center. No
mutations were identified.
Array comparative genomic hybridization was carried
out with a commercially available array designed to de-
tect copy number imbalances (losses or gains) across
the whole genome (NimbleGen 720K V.3.1, Roche
NimbleGen System Inc., Madison, WI, USA). The array
contains 720,000 oligonucleotides with a median probe
space of approximately 2.5kb that represents coding
and noncoding human sequences in the genome (con-
tent sourced from the University of California, Santa
Cruz hg18 human genome: March 2006 National
Center for Biotechnology Information build 36, RefSeq
and GenBank databases). One normal female validated
DNA sample was used as an opposite sex control for
the analysis. Data interpretation was based on informa-
tion from University of California, Santa Cruz Genome
Browser [15], the Database of Genomic Variants [16]
and an internal copy database. A high sensitivity micro-
array was carried out with specific attention to the loci
of the known genes involved in hypogonadotropic
hypogonadism and nasal development including MSX1,
NRP2, ALX3 and ALX4. No chromosomal imbalances
of these regions were seen on this analysis.
At age 13 years and 11 months, treatment with intra-
muscular testosterone enanthate at 75mg a month was
begun and increased to the full adult replacement dose
over 29 months. With testosterone replacement, his
penile length increased to 9cm, pubic hair advanced to
Tanner stage 4, acne developed and he experienced an
overall improved sense of well-being. At the age of 17,
he is in a staged process of building a nose.
Discussion
In this case report, we describe what we believe to be
the third case identified of arhinia with hypogonadism.
In contrast to the previous report [7], we have do-
cumented hypogonadotropic hypogonadism with paired
testosterone and gonadotropin levels. Though it is
assumed that the two patients previously reported by
Graham and Lee [7] also had hypogonadotropic hypo-
gonadism, gonadotropin levels were not measured;
therefore, primary hypogonadism was not excluded.
McGlone reported the case of a child with micropenis
and low basal gonadotropin levels measured at an un-
defined age, but the levels were normal upon luteinizing
hormone-releasing hormone stimulation [4]. One other
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arhinia and bilateral undescended testicles, but no other
biochemical evaluation [17]. Also in the first case
reported by Graham and Lee [7], no genetic testing was
performed, and in the second case, only a karyotype
with fluorescent in situ hybridization for mutations in
KAL1 was obtained. In our case, we have performed an
extensive investigation into the genes associated with
hypogonadotropic hypogonadism as well as copy num-
ber. Lastly, both previously reported cases by Graham
and Lee were classified as Bosma syndrome, an associ-
ation of arhinia with microphthalmia [7]. Our patient
does not have Bosma syndrome, and therefore, the gen-
etic basis may differ from our case.
Embryonic development of the nose is complex. Be-
ginning at the fourth week of gestation, the frontonasal
processes appear and slowly elevate into the dorsum and
apex of the nose [5]. During the fifth week of gestation,
the nasal placodes invaginate forming the nasal pits [5].
The pits deepen and mesenchyme in the margins of the
pits gives rise to the medial and lateral nasal processes
[5]. The medial processes fuse to form the nasal septum
and medial aspect of the upper lip while the lateral
processes form the alae of the nose [5].
In embryonic development, neurons that produce
gonadotropin-releasing hormone (GnRH) migrate along
the olfactory neurons, which act as axonal guides, from
their origin at the nasal placode to the hypothalamus
[10]. The vomeronasal nerve travels from the nasal epi-
thelium, crosses the cribriform plate, and then sends
fibers dorsally to the olfactory bulb [9]. Fibers of the
caudal vomeronasal nerve travel ventrally to the hypo-
thalamus along with the GnRH-producing neurons
[10]. Several factors have been identified that aid in
GnRH neuronal migration, including anosmin-1, fibro-
blast growth factor signaling, neural crest adhesion
molecules, and nasal embryonic luteinizing hormone-
releasing hormone factor; however, the exact regulation
of the migratory process is unknown [9].
Based on the current understanding of nasal and GnRH
neuron development, we would anticipate that patients
with arhinia would also have congenital hypogonadotropic
hypogonadism. Given that hypogonadotropic hypogonad-
ism is much more common than arhinia and several
genetic mutations have been documented in cases of
hypogonadotropic hypogonadism, we began by looking for
mutations in the known genes. Because no mutations were
identified in the genes known to cause hypogonadotropic
hypogonadism, we proceeded to a genome-wide array to
look for copy number variants; however, this revealed no
abnormalities that might be attributed to arhinia and
hypogonadotropic hypogonadism.
We hypothesize that the phenotype of our patent
results from inadequate development of the nasalplacode or related structures that interfere with either
development or migration of GnRH neuron precur-
sors. The genes directing these events presumably
act at a much earlier point in development than
those related to Kallmann syndrome and its variants.
Although we found no gene abnormalities, point muta-
tions or small deletions that significantly alter gene ex-
pression could still be present, but would be missed by
chromosomal microarray.
Conclusion
Arhinia is a rare congenital malformation that to date
has not been associated with an identifiable genetic ab-
normality. While we did not find a genetic explanation
with our current analysis, it is still very likely that the
two entities are a result of a common genetic cause. It is
possible in the future that, as new genetic loci for
hypogonadotropic hypogonadism and nasal develop-
ment are identified, the exact mechanism will become
apparent.
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